Annual report pursuant to Section 13 and 15(d)

Note 22 - Agreements (Details Textual)

v3.8.0.1
Note 22 - Agreements (Details Textual)
 1 Months Ended 12 Months Ended
Mar. 03, 2017
$ / shares
shares
Mar. 31, 2017
$ / shares
shares
Jul. 31, 2014
USD ($)
Sep. 30, 2013
Aug. 31, 2013
May 31, 2013
Jul. 31, 2012
USD ($)
shares
Dec. 31, 2011
USD ($)
Nov. 30, 2009
Jan. 31, 2002
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2015
USD ($)
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001                   $ 0.001 $ 0.001  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 1.19    
Research and Development Expense                     $ 4,513,842 $ 7,138,080 $ 10,562,729
Minimum [Member]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 0.01    
Maximum [Member]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     3.04    
Series NN Warrants [Member]                          
Class of Warrant or Right, Term   5 years                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares   $ 1.50                 $ 1.50    
Series NN Warrants [Member] | UCSD [Member]                          
Class of Warrant or Right, Term 5 years                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,000,000 1,000,000                 1,000,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.50                        
Reliable Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term                 10 years        
Long-term Contract for Supplies, Option to Extend, Term                 3 years        
Long-term Contract for Supplies, Resolution Term                 60 days        
Purchases Under Manufacture and Supply Agreement                     $ 0 1,100,000 225,000
Nordion Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term           3 years              
Purchases Under Clinical Supply Agreement                     0 43,000 244,000
PETNET Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term         3 years                
Purchases Under Manufacturing Agreement                     0 826,000 855,000
OsoBio Supply Agreement [Member]                          
Long-term Contract for Supplies, Resolution Term       60 days                  
Purchases Under Manufacturing Agreement                     250,000 1,200,000 472,000
Gipharma Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term       3 years                  
Long-term Contract for Supplies, Renewal Term       1 year                  
Purchases Under Service and Supply Master Agreement                     14,000 149,000 677,000
Tc99m Tilmanocept License Agreement [Member]                          
License Issue Fee                   $ 25,000      
License Maintenance Fee                   25,000      
Minimum Annual Royalty                   $ 25,000      
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member]                          
License Costs                     4,000 2,000 1,000
Tilmanocept License Agreement [Member]                          
License Issue Fee     $ 25,000                    
License Maintenance Fee     25,000                    
Minimum Annual Royalty     $ 25,000                    
Research and Development Expense                     253,000 199,000 152,000
Astra Zeneca Agreement [Member]                          
License Costs               $ 5,000,000          
Research and Development Expense                     70,000 116,000 80,000
Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones               6,500,000          
Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales               $ 11,000,000          
Alseres Pharmaceuticals Agreement [Member]                          
Research and Development Expense                     $ 0 $ 0 $ 5,000
Sublicense Execution Payment, Cash Paid             $ 175,000            
Stock Issued During Period, Shares Issued for Sublicense Fee | shares             300,000            
Milestone Payments, Maximum, Cash             $ 2,900,000            
Milestone Payments, Maximum, Cash, At the Time of Product Registration or Upon Commercial Sales             $ 2,500,000            
Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee | shares             1,150,000            
Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee, At the Time of Product Registration or Upon Commercial Sales | shares             950,000            
Employment Agreement [Member] | Minimum [Member]                          
Ratio of Entitled Salary                     1.3    
Employment Agreement [Member] | Maximum [Member]                          
Ratio of Entitled Salary                     3    
Loss Contingency, Estimate of Possible Loss                     $ 2,500,000